Twist Bioscience (NASDAQ:TWST) Trading Up 9.5% – Still a Buy?

Twist Bioscience Co. (NASDAQ:TWST)’s share price traded up 9.5% during trading on Wednesday . The company traded as high as $46.91 and last traded at $46.81. 123,251 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 617,160 shares. The stock had previously closed at $42.75.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TWST shares. Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Evercore ISI raised their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Scotiabank lifted their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Stock Up 6.0 %

The company has a market capitalization of $2.69 billion, a PE ratio of -12.59 and a beta of 1.85. The firm has a 50-day moving average of $46.42 and a two-hundred day moving average of $46.33.

Insider Activity

In other news, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $64,580.80. Following the sale, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at approximately $2,034,652. This represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Chess sold 3,600 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $47.26, for a total value of $170,136.00. Following the completion of the transaction, the director now directly owns 21,641 shares in the company, valued at $1,022,753.66. This trade represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 89,640 shares of company stock valued at $4,123,772. Company insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience in the third quarter valued at approximately $34,000. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience during the 2nd quarter valued at about $61,000. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the third quarter worth approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.